At the time of writing, Day One Biopharmaceuticals Inc [DAWN] stock is trading at $6.58, up 1.54%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DAWN shares have gain 3.95% over the last week, with a monthly amount drifted -7.84%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on October 09, 2024, when Needham reiterated its Buy rating and also boosted its price target to $33 from $32. Previously, BofA Securities upgraded its rating to Buy on August 01, 2024, and elevated its price target to $24. On April 24, 2024, Needham reiterated its Buy rating and revised its price target to $33 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $9 on April 25, 2023. CapitalOne initiated its recommendation with a Overweight and recommended $40 as its price target on February 08, 2023. In a note dated December 15, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $35 on this stock.
For the past year, the stock price of Day One Biopharmaceuticals Inc fluctuated between $6.08 and $16.76. Currently, Wall Street analysts expect the stock to reach $38.8 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $6.58 at the most recent close of the market. An investor can expect a potential return of 489.67% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.15 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Day One Biopharmaceuticals Inc [NASDAQ:DAWN] has a current ratio of 10.62. Also, the Quick Ratio is 10.55, while the Cash Ratio stands at 0.7. Considering the valuation of this stock, the price to sales ratio is 4.12, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Merendino Lauren, Chief Commercial Officer, that happened on May 16 ’25 when 3927.0 shares were sold. GENERAL COUNSEL, Dubow Adam completed a deal on May 16 ’25 to sell 4552.0 shares. Meanwhile, COO, CFO AND SECRETARY York Charles N II sold 4282.0 shares on May 16 ’25.
